B7-33 is a linear synthetic peptide analog of relaxin-2 B-chain extensively used in pre-clinical research to investigate RXFP1 binding, preferential ERK1/2 phosphorylation over cAMP, matrix metalloproteinase expression, and fibrotic tissue responses. This research-grade peptide is produced under stringent GMP-compliant conditions and provided as a lyophilized powder to ensure superior purity, stability, and reliability in experimental applications.
Engineered solely for preclinical investigations, each batch of B7-33 undergoes a comprehensive quality assessment and includes complete documentation, including a Certificate of Analysis (COA), purity data, and structural verification.
Scientific Overview
B7-33 binds RXFP1 and selectively activates downstream signaling cascades in laboratory research settings. Peer-reviewed preclinical literature has examined B7-33 in the following experimental contexts (pubmed.ncbi.nlm.nih.gov):
- Preferential activation of the pERK pathway over cAMP in RXFP1-expressing cell lines
- Modulation of extracellular matrix turnover via matrix metalloproteinase upregulation in in vitro assays
- Observation of fibrotic remodeling responses in cardiac, pulmonary, and renal preclinical models
- Investigation of vascular smooth muscle signaling mechanisms in ex vivo preparations
- Examination of inflammatory and apoptotic pathway regulation in stress-challenged cell and tissue models
Why Researchers Choose Our B7-33
For laboratories requiring dependable B7-33 research peptide, our manufacturing process prioritizes reproducibility and scientific precision. Every batch is confirmed for:
- Purity ≥99% by HPLC
- Structural identity via mass spectrometry
- Third-party Certificate of Analysis (COA) available per lot
For Research Use Only. Not for human use.
Statements regarding B7-33 have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Explore our testing protocols in About Peptides > Rigorous Testing.
Literature-Referenced Experimental Observations (Reported findings from peer-reviewed preclinical studies only — not claims of therapeutic use or efficacy)
- Selective RXFP1 agonism with observed pERK pathway preference and reduced cAMP activation in endogenous receptor cell models (DOI: 10.1039/C5SC04754D)
- Observed reduction in adverse cardiac remodeling markers, including cardiomyocyte death and endoplasmic reticulum stress indicators, in murine experimental models (DOI: 10.1161/JAHA.119.014034)
- Observed modulation of organ fibrosis markers in rodent heart and lung model systems with potency comparable to native relaxin-2 in vitro (DOI: 10.1039/C5SC04754D)
- Observed endothelium-dependent signaling responses in isolated mesenteric artery ex vivo preparations (DOI: 10.1016/j.ejphar.2017.04.028)
- Utility in investigating RXFP1-mediated vascular smooth muscle signaling without broader receptor engagement
- Application in examining extracellular matrix modulation pathways across multiple tissue model systems
